Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis.
about
Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinomaRisk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular CarcinomaModel based on γ-glutamyltransferase and alkaline phosphatase for hepatocellular carcinoma prognosis.Elevated CA19-9 Is Associated With Increased Mortality In A Prospective Cohort Of Hepatocellular Carcinoma Patients.Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma.Using serum α-fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: what is the most optimal cutoff?Sensitive electrochemical immunosensor based on three-dimensional nanostructure gold electrode.Importance of SALL4 in the development and prognosis of hepatocellular carcinoma.Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma.Resection and transplantation for hepatocellular carcinoma: factors influencing surgical options.Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner.Preoperative serum α-fetoprotein and prognosis after hepatectomy for hepatocellular carcinoma.Double primary hepatic cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) in a single patient: A case report.Assessing prognostic significance of preoperative alpha-fetoprotein in hepatitis B-associated hepatocellular carcinoma: normal is not the new normal.Persistent elevated C-reactive protein after treatment is an independent marker of a poor prognosis in patients with hepatocellular carcinoma.NLRC and NLRX gene family mRNA expression and prognostic value in hepatocellular carcinoma.The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma.Prognostic factors in patients with HBV-related hepatocellular carcinoma following hepatic resection.Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection.
P2860
Q28073769-EC5A585E-98CD-4915-A38A-B5D6B201FFA4Q28550305-FD7608C3-B8BD-42BA-AE05-4FE65E15A3CDQ34067936-B23161BC-8CA2-41CE-A386-0A01719330F2Q34667817-2634B3EB-AFA5-4923-A137-3498FFA47081Q34847211-A8E95231-E97B-40BD-B61C-D1614167F2A0Q34851700-8414D32E-F5F8-46D8-AD80-750DA332215EQ35148136-4AD819BB-27D9-4EA5-8F81-297DF10A9D42Q35212806-2DDBE6D5-BF59-49A6-ADEE-85A2E4F24063Q36650831-6AAFF376-E718-4B5C-A46A-D1474EA26DCAQ38120426-4BEDFA20-12A0-4BEE-95FD-49603F30674BQ38206274-196BFE30-96DA-45C6-A8BD-8CFE060A83C3Q39534358-67C5B104-1924-48EC-A18E-68DA5122C710Q40842666-C580D77C-21DD-46C5-9959-0239DA83C6C4Q40914145-F21E902B-61EE-42E7-92A6-C17039A1FA4FQ42255569-05E41E09-C90D-48C7-B5C0-64BB5317059AQ46679276-C61AAA97-C6F6-4983-9832-7022DE38C896Q47146232-46A615EF-28DF-4C86-98C6-7B61A51E9057Q52685824-14303FDE-F683-4178-ABBB-853E9EE23EB1Q55234213-05F9F6DC-94A3-478F-84CD-D4C1407D0D4EQ55505675-DDEF80EF-3A04-48A8-9955-CA596279B9A6
P2860
Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Is serum alpha-fetoprotein use ...... and competing risks analysis.
@en
Is serum alpha-fetoprotein use ...... and competing risks analysis.
@nl
type
label
Is serum alpha-fetoprotein use ...... and competing risks analysis.
@en
Is serum alpha-fetoprotein use ...... and competing risks analysis.
@nl
prefLabel
Is serum alpha-fetoprotein use ...... and competing risks analysis.
@en
Is serum alpha-fetoprotein use ...... and competing risks analysis.
@nl
P2093
P2860
P1476
Is serum alpha-fetoprotein use ...... s and competing risks analysis
@en
P2093
Da-Lim Yoon
Han Chu Lee
Kang Mo Kim
Seungbong Han
Sung-Gyu Lee
Young-Hwa Chung
Young-Joo Lee
Young-Suk Lim
Yung Sang Lee
P2860
P2888
P304
P356
10.1245/S10434-012-2416-1
P50
P577
2012-05-30T00:00:00Z
P5875
P6179
1019372341